Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis
← catalyst calendarSponsored by Precigen, Inc (industry) · PGEN — their whole pipeline →. With National Cancer Institute (NCI).
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
38actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-03-16 | actual | When the study began enrolling |
| Primary completion | 2024-06-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-05 | estimated | The whole study's end, after follow-up |
| First posted | 2021-01-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Recurrent Respiratory Papillomatosis
- Papillomavirus Infections
- Papillomaviridae
Interventions
- Drug: PRGN-2012 - Phase I; Dose Level 1
- Drug: PRGN-2012 - Phase I; Dose Level 2
- Drug: PRGN-2012 - Phase II; Dose Level 2
Primary outcomes
what the primary-completion date above is the date OFDetermine the percentage of subjects with a complete response following treatment with PRGN-2012
measured 1 year
Determine the incidence of dose limiting toxicities to evaluate safety and identify RP2D of PRGN-2012
measured 28 days
Publications
- PMID 39855244 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · PGEN's whole pipeline · Catalyst calendar · Every registered study · What changed